QFY pens major deal with Harvey Norman

Published 02-OCT-2017 12:10 P.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Quantify Technology (ASX:QFY) has signed an agreement with Harvey Norman’s largest franchisee, Harvey Norman Commercial Division (HNCD), to promote and sell its products in NSW and ACT.

The deal could see HNCD sell in the vicinity of $20-$30 million worth of QFY’s products to commercial and residential development projects, a key market the company has been targeting in its promotional efforts to date.

As part of the deal, QFY will set up a demonstration facility at HNCD’s showroom in NSW to take advantage of HNCD’s widespread sales network. The agreement includes the potential to consult Harvey Norman’s other commercial franchises in other states as part of creating a country-wide sales pipeline.

With a market cap of $4.34 billion, and with operations spanning New Zealand, Europe and south-east Asia, Harvey Norman is Australia’s largest furniture and household appliance retailer, which makes today’s announcement a potential catalyst for QFY share price movement.

However, QFY’s commercialisation ambitions are still in the early stages, so investors should seek professional financial advice if considering this stock for their portfolio.

As a result of the new agreement, both HNCD and QFY estimate potential sales of $20-$30 million per year over the next three to five years. Formal distribution and supply agreements are still being finalised, with contracts specific to projects and/or individual developers.

The deal means that HNCD will extend its building automation offerings to new and existing customers, primarily large scale builders and developers in the high rise and home builder sector. Many of its existing customers are looking to include Internet of Things (IoT) technology into their developments as demand increases.

A major boost to QFYs commercialisation program

Today’s news is set to significantly accelerate the company’s commercialisation program as it provides entry to an expansive network of HNCD’s customers, consultants and contractors. HNCD NSW/ ACT is the single largest Harvey Norman franchise and provides an extensive selection of brand name products to builders, developers, architects and designers, with a projected turnover for this financial year of $300 million.

Regarding the announcement, QFY Managing Director Mark Lapins said: “We see enormous potential in partnering with HNCD. This deal significantly advances our commercialisation efforts and gives us a large pipeline of residential project customers in NSW and the ACT and potentially, Australia-wide.”

HNCD’s Principal, Alan Stephenson said the following: “Harvey Norman enjoys a strong market and a loyal customer base supported by an extensive sales and marketing team. We see increasing demand from customers for Home Automation solutions and Quantify Technology, at that cutting edge, will allow us to enhance our reputation of supplying and supporting leading brands. We think this Agreement will significantly enhance the value we offer our clients”.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free